Laboratorios Farmaceuticos Rovi, S.A.
0ILL.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.44B
Close$
$47.01
18.2% downside
Current Fair Value
18.2% downsideOvervalued by 18.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.44 Billion |
|---|---|
| Enterprise Value | $3.44 Billion |
| Dividend Yield | $0.78 (1.34%) |
| Earnings per Share | $2.75 |
| Beta | 0.22 |
| Outstanding Shares | 51,144,431 |
Return
| Return on Equity | 26.43% |
|---|---|
| Return on Assets | 16.43% |
| Return on Invested Capital | 27.34% |
Valuation & Multiples
| P/E Ratio | 16.04 |
|---|---|
| PEG | 6.5 |
| Price to Sales | 3.83 |
| Price to Book Ratio | 4.11 |
| Enterprise Value to Revenue | 4.45 |
| Enterprise Value to EBIT | 14.8 |
| Enterprise Value to Net Income | 18 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$177.87 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Laboratorios Farmaceuticos Rovi, S.A.
2,232 employees
CEO: Juan Lopez-Belmonte Encina Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical enterprise that specializes in the research, development, manufacturing, and global commercialization of its own medicinal products. The company's operations span Spain, t...